Statins Show Benefits in Reducing Heart Dysfunction from Anthracyclines
Contact: Nicole Napoli, firstname.lastname@example.org, 202.669.1465
New Orleans (Mar 04, 2023) -
Among people receiving chemotherapy regimens containing anthracyclines for lymphoma, those who took the cholesterol-lowering drug atorvastatin for one year were significantly less likely to show evidence of heart dysfunction than those who took a placebo, according to a study presented at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology.
Damage to the heart is a relatively common side effect of anthracycline treatment and can lead to heart dysfunction and then heart failure, a condition in which the heart muscle becomes too weak to pump blood effectively. The trial results suggest that statins can help to lessen the effects of this cardiac damage, particularly in people who are at elevated risk of heart problems due to older age, higher body mass index or taking higher doses of anthracyclines, according to researchers.
“We believe that patients with lymphoma who are treated with anthracyclines and are at high risk of cardiac dysfunction and heart failure would benefit from statin therapy,” said Marielle Scherrer-Crosbie, MD, professor of medicine at the Hospital of the University of Pennsylvania and the study’s co-lead author. “I think it’s an impactful study that will lead to more prescription of statins in patients.”
Anthracyclines are the most common chemotherapy used to treat lymphoma and are also used for several other cancer types. Researchers have long sought interventions to reduce the risk of cardiac toxicity associated with this class of drugs, with limited success. Another recent study, which had a different endpoint and largely focused on patients treated for breast cancer, found that statins did not reduce cardiotoxicity. Compared with breast cancer, treatment strategies for lymphoma more often include anthracyclines and involve higher doses of these drugs.
For the new trial, called STOP-CA, researchers enrolled 300 patients with lymphoma undergoing treatment with anthracyclines at a median dose of 300 mg/m2. Half were assigned to take 40 mg of atorvastatin and half took a placebo daily, starting before their first dose of anthracyclines and continuing for one year. Patients’ left ventricle ejection fraction (LVEF)—a measure of the heart’s pumping ability—was assessed at baseline and one year. A total of 286 patients completed the study.
The trial’s primary endpoint was the proportion of patients who experienced a decline in LVEF of 10% or more (to less than 55%, near the lower limit of normal LVEF) from baseline to one year. This degree of reduction occurred in only 9% of those taking atorvastatin, whereas patients taking a placebo were nearly three times as likely (22%) to see this level of LVEF decline. The trial’s secondary endpoint, a reduction in LVEF of 5% or more to less than 55% from baseline to one year, was also significant in favor of atorvastatin.
“This effect will also need to be confirmed in terms of symptomatic heart failure, but the endpoint we chose is clinically relevant because those rates of decline in LVEF are associated with later symptomatic heart failure,” Scherrer-Crosbie said. “There is a clear protective effect of atorvastatin in terms of cardiac dysfunction in patients with lymphoma treated with anthracyclines.”
The results showed no significant difference in the rates of adverse events such as muscle pain or renal failure.
At one year, patients who took statins had an average ejection fraction that was 1.3% higher than patients who took a placebo. This absolute difference between the two groups was statistically significant; however, researchers said it is not a large enough magnitude to be clinically relevant when viewed across the entire patient population, though the difference may be greater among subgroups of patients. This finding underscores the importance of identifying and treating populations of patients that might benefit most from statins, researchers said.
Further studies are needed to elucidate which subgroups of patients may benefit most from statin use and examine whether statin therapy prevents symptomatic heart failure. Researchers also said the current study excluded people with below-normal LVEF at baseline and those with an indication for statins, meaning the population of patients included likely had better overall heart health than the general population of people with lymphoma.
In addition, more research is needed to determine the optimal timing and duration of statin therapy during cancer treatment to assess whether statins are beneficial in children treated with anthracyclines and to determine whether the benefits observed in this study extend to other cancer types.
The study was funded by the National Institutes of Health.
Scherrer-Crosbie will be available to the media in a press conference on Saturday, March 4, at 10:45 a.m. CT / 16:45 UTC in the Rivergate Room.
Tomas Neilan, co-lead author, will present the study, “Statins to Prevent the Cardiotoxicity from Anthracyclines: The STOP-CA Trial,” on Saturday, March 4, at 9:30 a.m. CT / 15:30 UTC in the Great Hall.
ACC.23/WCC will take place March 4-6, 2023, in New Orleans, bringing together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention. Follow @ACCinTouch, @ACCMediaCenter and #ACC23/#WCCardio for the latest news from the meeting.
The American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all. As the preeminent source of professional medical education for the entire cardiovascular care team since 1949, ACC credentials cardiovascular professionals in over 140 countries who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. Through its world-renowned family of JACC Journals, NCDR registries, ACC Accreditation Services, global network of Member Sections, CardioSmart patient resources and more, the College is committed to ensuring a world where science, knowledge and innovation optimize patient care and outcomes. Learn more at ACC.org.